CJC-1295 and Ipamorelin: The Richard Norton Coroner Finding, the Human Evidence, and Legal Status

On October 28, 2026, a coroner in Victoria, Australia, found that the actor and martial artist Richard Norton died after an injection of CJC-1295 and ipamorelin, two growth-hormone peptides sold together in one vial. The coroner accepted a pathologist's finding of anaphylaxis, a severe allergic reaction, which led to cardiac arrest. Norton was 75 and had been injecting more than his prescribed dose.

Both peptides make the pituitary gland release more growth hormone. Neither is approved as a medicine in the United States or Australia. The published human research on them is small: two short CJC-1295 studies in healthy adults, a CJC-1295 trial stopped in 2006 after a participant died, and one ipamorelin trial after bowel surgery that found no significant benefit. We found no published randomized trial of either peptide, or the blend, for muscle, recovery, sleep, or aging, the uses clinics advertise.

In the U.S., neither peptide is among the six covered by the HHS compounding policy announced on October 28, 2026. This article covers what the coroner found, what the human data show, and where the two peptides stand legally. For how the drugs work, see Peptides vs. Growth Hormone. For flushing after injections, see Flushing After CJC-1295 or Ipamorelin.

The written finding, published by the Coroners Court of Victoria, sets out this timeline:

• March 11, 2025: Norton saw a doctor about peptide therapy. He had used peptides prescribed by another practitioner before, for fatigue, slow recovery, shoulder pain, and loss of muscle.
• March 15: He signed a consent form. It listed anaphylaxis as one of the risks of the CJC-1295 and ipamorelin product.
• March 19: After more blood tests and a coronary calcium scan, the doctor prescribed a 2,000 mcg CJC-1295 and ipamorelin solution, 0.1 mL injected under the skin each weekday evening. The doctor said the product came from a licensed compounding pharmacy in Queensland.
• March 28, afternoon: Norton told a nurse at the clinic that he had been injecting double the prescribed dose. The nurse told him to return to the prescribed dose the following week.
• March 28, about 9 p.m.: After his second injection that day, he said he felt hot and flushed, then collapsed. Paramedics found him in cardiac arrest, and his heart was restarted at 9:55 p.m., about 45 minutes after emergency services were called.
• March 30: He died at the Alfred Hospital in Melbourne.

Hospital records describe reactions that built over several days. There was redness and swelling at the injection site at first, then whole-body flushing, and on the morning of March 28, flushing with chest tightness and shortness of breath that eased after he used his asthma inhaler. In hospital, his tryptase level, a blood marker released during allergic reactions, was high.

The forensic pathologist found evidence of anaphylaxis at autopsy. Because the allergic symptoms started after the peptide therapy began, he favored the injections as a possible cause. He also found hypertrophic cardiomyopathy, a thickened heart muscle that raises the risk of dangerous heart rhythms, and said it and Norton's asthma could have contributed. Toxicology tests could not detect the peptides themselves.

Coroner David Ryan wrote that he was satisfied the death was triggered by the CJC-1295 and ipamorelin injection, that Norton had been taking more than his prescribed dose, and that the injection caused an anaphylactic reaction that led to cardiac arrest. The official cause of death lists complications of a cardiac arrest outside hospital and anaphylaxis, with asthma and hypertrophic cardiomyopathy as contributing conditions.

One death does not tell anyone how often these peptides cause anaphylaxis. Nobody knows how many people inject them, so there is no way to turn a single case into a rate. Norton was also 75, with asthma and a heart muscle condition. He had told a nurse he was taking double the prescribed dose, and his wife told hospital staff he had been injecting twice a day.

The finding also cannot say which ingredient caused the reaction. The vial held two peptides, and compounded and gray-market products can contain other substances or impurities. Because the peptides could not be measured in his blood, the link rests on timing, symptoms, and the autopsy.

The case is not isolated, though. Australia's Therapeutic Goods Administration (TGA) told the coroner it had received six reports of anaphylaxis or hypersensitivity in people using CJC-1295 and ipamorelin, BPC-157 or thymosin beta-4, or TB-500, including three cases of anaphylaxis with CJC-1295 and ipamorelin, not counting Norton. In the U.S., the FDA has said it identified serious adverse events tied to CJC-1295, including a faster heart rate and a body-wide reaction in which blood vessels widen.

The pattern in Norton's records matters for anyone who injects these products. Flushing that spreads beyond the injection site, chest tightness, wheezing, throat or tongue swelling, or feeling faint can be signs of anaphylaxis. Those symptoms need emergency care, not another dose.

CJC-1295 is a lab-made version of growth-hormone-releasing hormone (GHRH), the brain signal that tells the pituitary to release growth hormone. The original version, also called DAC:GRF, was chemically modified to last for days in the blood. Products sold as "CJC-1295 without DAC" are a different, shorter-acting peptide.

The main published human data come from two randomized, placebo-controlled studies in healthy adults aged 21 to 61, reported in the Journal of Clinical Endocrinology & Metabolism in 2006. The studies lasted 28 and 49 days. One injection raised average growth hormone levels 2- to 10-fold for six days or more and raised IGF-1, a hormone made in response to growth hormone, 1.5- to 3-fold for 9 to 11 days. The drug's half-life was 5.8 to 8.1 days, and no serious adverse reactions were reported.

The developer, the Canadian company ConjuChem, then tested CJC-1295 in a Phase 2 trial in people with HIV who had excess belly fat. The trial enrolled 192 people at sites in North and South America. ConjuChem stopped it on July 17, 2006, after a participant at a site in Argentina died, the HIV news service aidsmap reported. At the time, the cause of death and whether it was related to the drug were still under investigation. The trial registry lists the study as terminated.

A related GHRH drug from the same period, Theratechnologies' tesamorelin, kept going and was approved by the FDA in 2010 as Egrifta, for excess belly fat in adults with HIV.

Ipamorelin works through a different route. It mimics ghrelin, a gut hormone, and activates the ghrelin receptor on the pituitary to release growth hormone. Its 1998 description as the first selective growth hormone secretagogue came from laboratory and animal studies.

Its main human trial was in a different setting. Helsinn tested it in 117 adults recovering from bowel surgery, to see if it would help the gut start working again. Patients got 0.03 mg per kilogram into a vein twice a day for up to seven days. The median time to the first tolerated solid meal was 25.3 hours on ipamorelin and 32.6 hours on placebo, a difference that was not statistically significant. Adverse events of any kind were reported in 87.5% of the ipamorelin group and 94.8% of the placebo group, and the authors called the drug well tolerated.

The FDA has described the evidence differently. In explaining its safety concerns, the agency said a published study of intravenous ipamorelin for gut motility identified serious adverse events, including death. The FDA also said ipamorelin may trigger immune reactions because it can clump or carry impurities. The agency added that it lacks safety data for other injection routes.

Because CJC-1295 and ipamorelin have no approved labels, the closest guide to class risks is tesamorelin, the approved GHRH drug. Its label is a guide, not proof, since it is a different molecule given at studied doses.

The current Egrifta WR label lists:

• Allergic reactions: reported in 4% of patients in trials, including itching, redness, flushing, hives, and rash. The label tells patients to stop the drug and get prompt care if one is suspected.
• Fluid retention: swelling, joint pain, and carpal tunnel syndrome.
• Higher blood sugar: 5% of patients on tesamorelin and 1% on placebo reached an HbA1c of 6.5% or higher by week 26.
• Raised IGF-1: the long-term effects of prolonged high IGF-1 are unknown, so the label calls for monitoring.
• Cancer caution: the drug should not be used in people with active cancer.

The Medical Board of Australia's outside expert, clinical professor Alistair Vickery, gave a similar list for CJC-1295 and ipamorelin in the Norton case: nerve, muscle, or joint pain, swelling, carpal tunnel syndrome, numbness or tingling, headaches, higher glucose, heart disease, diabetes, and, rarely, anaphylaxis. He wrote that there is "insufficient evidence that CJC1295/Ipamorelin is safe, effective or beneficial for human use."

Neither peptide is an FDA-approved drug. A compounding pharmacy working under section 503A of federal drug law can generally use a bulk ingredient only if it has an official USP monograph, is part of an approved drug, or is on the FDA's 503A bulks list.

FDA keeps a page on bulk ingredients with safety concerns, last updated April 22, 2026. It lists CJC-1295 as a substance that was once in Category 2, the group FDA says raises significant safety risks. The people who nominated it for compounding later withdrew the nomination. Ipamorelin acetate is in the same withdrawn group for 503A pharmacies. For larger 503B outsourcing facilities, it has been in Category 2 since September 29, 2023. FDA's May 14, 2026 list of substances under evaluation for 503A compounding, known as Category 1, includes neither peptide. FDA says its interim policy of not taking action applies to substances in Category 1.

Neither was among the seven peptides the FDA's Pharmacy Compounding Advisory Committee reviewed in July 2026. Neither is among the six peptides in HHS's October 28 enforcement policy, which covers BPC-157, TB-500, epitalon, KPV, MOTS-c, and semax. That policy was published in the Federal Register on October 30, 2026 (our explainer).

For athletes, the 2026 World Anti-Doping Agency list names both CJC-1295 and ipamorelin under growth hormone releasing factors (section S2.2.4), banned at all times, in and out of competition (peptides and sports).

In Australia, CJC-1295, ipamorelin, BPC-157, thymosin beta-4, and TB-500 are prescription-only medicines. They sit in Schedule 4 of the national Poisons Standard. None is on the Australian Register of Therapeutic Goods, the list of approved medicines. Australian doctors can still get unapproved products for patients through special pathways, such as the Authorised Prescriber Scheme.

The coroner wrote that he was not satisfied these peptides belong in Schedule 4, given the risks and the lack of evidence of benefit. He recommended that the TGA review peptides such as CJC-1295 and ipamorelin and consider tighter limits, such as moving them to Schedule 10, the category for "substances of such danger to health as to warrant prohibition of supply and use." That could ban human use except in clinical trials or other research.

Hospitals are seeing more cases. In October 2026, New South Wales Health said 1,180 people went to the state's emergency departments after taking unapproved peptides between July 2025 and September 2026. Monthly visits rose from 5 to almost 220. In New Zealand, the medicines regulator Medsafe has warned that many unapproved peptides, including CJC-1295 and ipamorelin, are illegal and potentially harmful. Health New Zealand now gives pharmacies injecting kits for people who use peptides without a prescription. It had handed out 2,300 by late October.

This article does not give dosing advice, and these products have no approved dose. If you are using CJC-1295, ipamorelin, or a blend, these points come straight from the record:

• Tell the clinician who manages your health, including any reactions so far. Norton's records show worsening reactions over several days before the fatal dose.
• Don't take more than prescribed. Norton had told a nurse he was injecting double his prescribed dose.
• Treat a whole-body reaction as a warning. Flushing with chest tightness, wheezing, shortness of breath, swelling of the lips, tongue, or throat, or feeling faint needs emergency care. In the U.S., call 911.
• Ask where the product came from. A licensed pharmacy made Norton's product. That still does not mean the product has been tested for safety and effectiveness the way an approved drug is. Vials sold online as "research use only" have even less oversight (what that label means).
• Mention asthma, heart disease, diabetes, or cancer history. The coroner listed Norton's asthma and heart muscle condition as contributing factors, and the tesamorelin label warns about blood sugar and active cancer.